MX2023005806A - Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras). - Google Patents
Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras).Info
- Publication number
- MX2023005806A MX2023005806A MX2023005806A MX2023005806A MX2023005806A MX 2023005806 A MX2023005806 A MX 2023005806A MX 2023005806 A MX2023005806 A MX 2023005806A MX 2023005806 A MX2023005806 A MX 2023005806A MX 2023005806 A MX2023005806 A MX 2023005806A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- kras mutant
- mutant cancers
- combination therapies
- provides combination
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115969P | 2020-11-19 | 2020-11-19 | |
| US202163154652P | 2021-02-26 | 2021-02-26 | |
| US202163158849P | 2021-03-09 | 2021-03-09 | |
| US202163173361P | 2021-04-10 | 2021-04-10 | |
| PCT/US2021/060151 WO2022109307A1 (en) | 2020-11-19 | 2021-11-19 | Treatment of kras mutant cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005806A true MX2023005806A (es) | 2023-07-31 |
Family
ID=81709695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005806A MX2023005806A (es) | 2020-11-19 | 2021-11-19 | Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras). |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240016781A1 (https=) |
| EP (1) | EP4247806A4 (https=) |
| JP (1) | JP2024500288A (https=) |
| KR (1) | KR20230148144A (https=) |
| AU (1) | AU2021381423A1 (https=) |
| CA (1) | CA3198938A1 (https=) |
| IL (1) | IL302925A (https=) |
| MX (1) | MX2023005806A (https=) |
| WO (1) | WO2022109307A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| EP4376839A4 (en) * | 2021-07-26 | 2025-10-15 | Vincerx Pharma Inc | SELECTIVE CDK9 INHIBITOR FOR THE TREATMENT OF RAS MUTANT CANCER |
| CN119522225A (zh) | 2022-09-29 | 2025-02-25 | 广州嘉越医药科技有限公司 | 大环衍生物及其应用 |
| IL319991A (en) * | 2022-10-03 | 2025-06-01 | Prelude Therapeutics Inc | Cancer treatment using combinations of SMARCA2 inhibitors and KRAS-targeted therapies |
| WO2024173833A1 (en) * | 2023-02-16 | 2024-08-22 | Mei Pharma, Inc. | Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563596B2 (en) * | 2006-06-21 | 2013-10-22 | Piramal Enterprises Limited | Enantiomerically pure compounds for the treatment of proliferative disorders |
| CN104220066A (zh) * | 2010-11-19 | 2014-12-17 | 皮拉马尔企业有限公司 | 紫杉醇和cdk抑制剂药物组合物 |
| CN105530931B (zh) * | 2013-07-12 | 2019-11-08 | 皮拉马尔企业有限公司 | 用于治疗黑素瘤的药物组合 |
| RU2726367C2 (ru) * | 2016-03-28 | 2020-07-13 | Пресидж Байосайенсиз, Инк. | Фармацевтические комбинации для лечения злокачественной опухоли |
| US20220175750A1 (en) * | 2018-04-23 | 2022-06-09 | The Regents Of The University Of California | Sustained release formulation for local delivery of cdk9 inhibitors |
| WO2020046966A1 (en) * | 2018-08-27 | 2020-03-05 | Kura Oncology, Inc. | Treatment of adenocarcinomas with mapk pathway inhibitors |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| AU2020271908B2 (en) * | 2019-04-11 | 2025-12-04 | Mei Pharma, Inc. | Voruciclib poly morphs and methods of making and using thereof |
| CA3148504A1 (en) * | 2019-08-08 | 2021-02-11 | Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center | Combination therapy for treatment of cancer |
| WO2022217133A1 (en) * | 2021-04-10 | 2022-10-13 | Mei Pharma, Inc. | Voruciclib dosing regimens and methods of treatment including the same |
-
2021
- 2021-11-19 WO PCT/US2021/060151 patent/WO2022109307A1/en not_active Ceased
- 2021-11-19 EP EP21895697.7A patent/EP4247806A4/en active Pending
- 2021-11-19 US US18/253,481 patent/US20240016781A1/en active Pending
- 2021-11-19 IL IL302925A patent/IL302925A/en unknown
- 2021-11-19 CA CA3198938A patent/CA3198938A1/en active Pending
- 2021-11-19 JP JP2023530278A patent/JP2024500288A/ja active Pending
- 2021-11-19 MX MX2023005806A patent/MX2023005806A/es unknown
- 2021-11-19 KR KR1020237020122A patent/KR20230148144A/ko active Pending
- 2021-11-19 AU AU2021381423A patent/AU2021381423A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021381423A1 (en) | 2023-06-22 |
| KR20230148144A (ko) | 2023-10-24 |
| WO2022109307A1 (en) | 2022-05-27 |
| US20240016781A1 (en) | 2024-01-18 |
| EP4247806A4 (en) | 2024-11-13 |
| IL302925A (en) | 2023-07-01 |
| JP2024500288A (ja) | 2024-01-09 |
| CA3198938A1 (en) | 2022-05-27 |
| EP4247806A1 (en) | 2023-09-27 |
| AU2021381423A9 (en) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005806A (es) | Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras). | |
| JOP20220142A1 (ar) | مثبطات kras g12c | |
| JOP20250246A1 (ar) | مثبطات kras | |
| MA55145B1 (fr) | Polythérapie incluant un inhibiteur de kras g12c et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
| CR20220354A (es) | Inhibidores de egfr | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| ZA202107579B (en) | Pharmaceutical combinations for the treatment of cancer | |
| MX2023010411A (es) | Inhibidores de erbb/btk. | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| WO2021243280A3 (en) | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 | |
| MX2023004309A (es) | Inhibidores de quinasa alk2 que contienen imidazol. | |
| MX2023001071A (es) | Tratamiento de la migraña. | |
| CR20240147A (es) | Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t | |
| MX2024000230A (es) | Inhibidores de cdk2. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| PH12022551052A1 (en) | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor | |
| MX2025001982A (es) | Inhibidores de kif18a y usos de estos | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| MX2020011912A (es) | Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc). | |
| WO2022251188A3 (en) | Imidazole-containing inhibitors of alk2 kinase | |
| WO2021015294A3 (en) | Combination therapy for cancer treatment | |
| MX2023002539A (es) | Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv). |